CA2301599C - Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands - Google Patents

Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands Download PDF

Info

Publication number
CA2301599C
CA2301599C CA002301599A CA2301599A CA2301599C CA 2301599 C CA2301599 C CA 2301599C CA 002301599 A CA002301599 A CA 002301599A CA 2301599 A CA2301599 A CA 2301599A CA 2301599 C CA2301599 C CA 2301599C
Authority
CA
Canada
Prior art keywords
dihydro
oxo
naphthyridine
carboxamide
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002301599A
Other languages
English (en)
French (fr)
Other versions
CA2301599A1 (en
Inventor
Pamela Albaugh
Robert W. Desimone
Gang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of CA2301599A1 publication Critical patent/CA2301599A1/en
Application granted granted Critical
Publication of CA2301599C publication Critical patent/CA2301599C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002301599A 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands Expired - Fee Related CA2301599C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91818097A 1997-08-25 1997-08-25
US08/918,180 1997-08-25
PCT/US1998/017513 WO1999010347A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Publications (2)

Publication Number Publication Date
CA2301599A1 CA2301599A1 (en) 1999-03-04
CA2301599C true CA2301599C (en) 2003-03-25

Family

ID=25439933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002301599A Expired - Fee Related CA2301599C (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Country Status (24)

Country Link
EP (1) EP1007526A1 (enExample)
JP (1) JP2001514181A (enExample)
KR (1) KR20010023313A (enExample)
CN (1) CN1268136A (enExample)
AP (1) AP2000001742A0 (enExample)
AU (1) AU753800B2 (enExample)
BG (1) BG104192A (enExample)
BR (1) BR9811362A (enExample)
CA (1) CA2301599C (enExample)
EG (1) EG21717A (enExample)
HU (1) HUP0003258A3 (enExample)
IL (1) IL134291A0 (enExample)
IS (1) IS5382A (enExample)
LV (1) LV12539B (enExample)
NO (1) NO20000822L (enExample)
NZ (1) NZ502548A (enExample)
OA (1) OA11293A (enExample)
PE (1) PE130999A1 (enExample)
PL (1) PL338783A1 (enExample)
SI (1) SI20270A (enExample)
SK (1) SK2162000A3 (enExample)
TW (1) TW574221B (enExample)
WO (1) WO1999010347A1 (enExample)
YU (1) YU10500A (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413956B1 (en) * 1999-05-06 2002-07-02 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides
US6448246B1 (en) 1999-05-25 2002-09-10 Neurogen Corporation Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
US6841558B2 (en) 2000-10-12 2005-01-11 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as HIV intergrase inhibitors
ATE430745T1 (de) 2000-10-12 2009-05-15 Merck & Co Inc Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
CZ20032338A3 (cs) * 2001-03-01 2004-08-18 Pfizeráproductsáinc Použití inversních agonistů GABA A v kombinaci s parciálními agonisty receptoru nikotinuŹ estrogenemŹ selektivními modulátory estrogenu nebo vitaminem E při léčení kognitivních poruch
AR036256A1 (es) 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
AU2003216049B2 (en) 2002-01-17 2008-07-17 Merck Sharp & Dohme Corp. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
EP1496836B1 (en) 2002-03-15 2008-09-24 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
WO2004106336A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides
WO2004106334A2 (en) * 2003-05-28 2004-12-09 Pfizer Products Inc. Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation
CA2954376C (en) * 2006-10-16 2019-06-11 Bionomics Limited Novel anxiolytic compounds
JP2010510314A (ja) * 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204162A1 (es) * 1972-05-08 1975-11-28 Yamanouchi Pharma Co Ltd Proceso para la preparacion de derivados de ampicilina
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
DD279875A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von aktivierten carbonsaeureestern
DD279887A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika
DD295360A5 (de) * 1987-07-03 1991-10-31 Akad Wissenschaften Verfahren zur Herstellung von aktivierten Carbonsäureestern
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative

Also Published As

Publication number Publication date
HUP0003258A2 (en) 2001-03-28
LV12539A (en) 2000-10-20
OA11293A (en) 2002-11-19
EG21717A (en) 2002-02-27
NO20000822D0 (no) 2000-02-18
CA2301599A1 (en) 1999-03-04
AU9117398A (en) 1999-03-16
AU753800B2 (en) 2002-10-31
NZ502548A (en) 2002-06-28
HUP0003258A3 (en) 2001-05-28
PL338783A1 (en) 2000-11-20
CN1268136A (zh) 2000-09-27
BR9811362A (pt) 2000-08-22
KR20010023313A (ko) 2001-03-26
SK2162000A3 (en) 2001-03-12
JP2001514181A (ja) 2001-09-11
SI20270A (sl) 2000-12-31
IS5382A (is) 2000-02-22
NO20000822L (no) 2000-04-13
PE130999A1 (es) 1999-12-16
YU10500A (sh) 2002-10-18
LV12539B (en) 2001-01-20
AP2000001742A0 (en) 2000-02-24
TW574221B (en) 2004-02-01
EP1007526A1 (en) 2000-06-14
WO1999010347A1 (en) 1999-03-04
IL134291A0 (en) 2001-04-30
BG104192A (en) 2001-05-31

Similar Documents

Publication Publication Date Title
US6399604B1 (en) Substituted 4-OXO-napthyridine-3-carboxamides; GABA brain receptor ligands
US6103903A (en) 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
CA2301599C (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
US6423711B1 (en) Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands
US6156898A (en) Substituted 1,4-dihydro-4-oxonicotinic carboxamides; GABA brain receptor ligands
JP5524071B2 (ja) 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
US6177569B1 (en) Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
JPH0841056A (ja) ６員の窒素含有ヘテロアリール−オキサゾリジノン類
US6414147B1 (en) 2-amino-9-alkylpurines: GABA brain receptor ligands
WO1994005665A1 (en) Certain aryl and cycloalkyl fused imidazopyrazinols; a new class of gaba brain receptor ligands
JP2003533524A (ja) ホスホジエステラーゼ阻害剤として有効な置換ピロロピリジノン誘導体
US6194427B1 (en) Substituted cycloalkyl-4-Oxonicotinic carboxamides; gaba brain receptor ligands
EP1107966B1 (en) Oxo-pyridoimidazole-carboxamides: gaba brain receptor ligands
MXPA00001598A (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
MXPA00008364A (en) Substituted cycloalkyl-4-oxonicotinic carboxamides;gaba brain receptor ligands
MXPA01001991A (en) Oxo-pyridoimidazole-carboxamides:gaba brain receptor ligands

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed